A trial of nivolumab for Hodgkin lymphoma (ANIMATE)
Please note - this trial is no longer recruiting patients. We hope to add results when they are available.
Cancer type:
Status:
Phase:
This trial is looking at whether nivolumab can improve treatment before a stem cell transplant for people with Hodgkin lymphoma.
More about this trial
- see how well nivolumab works as a salvage treatment
- see the number of people that are suitable to have a stem cell transplant following nivolumab treatment
- learn more about the side effects of nivolumab
Who can enter
- have Hodgkin lymphoma that has come back after your first chemotherapy treatment or it didn’t work very well
- are due to have, are having or have had (within 14 days), 2 cycles of chemotherapy as your first or second salvage treatment
- are well enough to have a stem cell transplant with your own cells
- are willing to use reliable contraception if there is any chance you or your partner could become pregnant
- are at least 16 years old
- joined part 1 of this trial
- have had 2 cycles of salvage chemotherapy for Hodgkin lymphoma (or 4 cycles of treatment if you had a drug called brentuximab vedotin)
- had the salvage chemotherapy but a PET-CT scan showed it didn’t work well enough to go on and have a stem cell transplant
- are well enough to have more chemotherapy
- are well enough to take part and to carry out all your normal activities apart from heavy physical work (performance status of 0 or 1)
- are willing to use reliable contraception during treatment with nivolumab and for up to 6 months afterwards if there is any chance that you or your partner could become pregnant
- have satisfactory blood test results
- have a type of Hodgkin lymphoma called nodular lymphocyte Hodgkin lymphoma
- have inflammation of the bowel or lung
- have an autoimmune condition apart from vitiligo, diabetes, or a problem with your thyroid gland that doesn’t need treatment
- are allergic to drugs called monoclonal antibodies
- have had surgery within 4 weeks of joining the trial
- have had a heart problem such as a heart attack in the last 6 months
- have had any other cancer in the last 3 years apart from basal cell skin cancer, squamous cell skin cancer or certain early cancers
- have an active hepatitis B or hepatitis C infection
- have HIV
- are pregnant or breastfeeding
- had salvage chemotherapy and the chemotherapy worked well
- had chemotherapy, radiotherapy or steroids of more than 10mg a day within 14 days of having a PET-CT scan
- have an active infection that needs treatment
- are having treatment to dampen down your immune system apart from creams, nose sprays or low dose steroids
- are having or have had an experimental treatment as part of another trial with 28 days of starting nivolumab
- have side effects from treatment that haven’t got better apart from hair loss or moderate tiredness
- are pregnant or breastfeeding
Trial design
- part 1 is for people having the usual salvage chemotherapy
- part 2 is for people whose salvage chemotherapy doesn’t work well enough to have a stem cell transplant
- might be suitable to join part 2 to have nivolumab if chemotherapy hasn’t worked well enough
- won’t be able to join part 2 if salvage chemotherapy worked well. You might go on to have a stem cell transplant.
- won’t have any more nivolumab if the scan shows treatment seems to have worked – you might then have a stem cell transplant
- will have 4 more cycles of nivolumab if it hasn’t worked well enough after the first 4 cycles
- stop treatment if your lymphoma got worse - your doctor will discuss other treatment options with you
For people having further nivolumab, you have more scans after treatment. Depending on these results, you:
- might then have a stem cell transplant if treatment worked well
- won’t have a stem cell transplant if treatment didn’t work well enough - your doctor will talk to you about other treatment options
- see how well the treatment is working
- look for biomarkers to predict who will benefit from treatment
Hospital visits
- medical history assessment
- pregnancy test
- physical examination
- blood tests
- heart trace (ECG)
- a test to measure your breathing
- pregnancy test
- PET-CT scan
- CT scan
- every 3 months for a year
- once a year for up to 2 years
Side effects
This is the first time people with Hodgkin lymphoma are having nivolumab before a stem cell transplant. So there might be some side effects we don’t know about yet. The trial team monitor you during treatment and afterwards. Contact your advice line or tell your doctor or nurse if any side effects are bad or not getting better.
Nivolumab can affect the immune system. It may cause inflammation in different parts of the body which can cause serious side effects. They could happen during treatment, or some months after treatment has finished. Rarely, these side effects could be life threatening.
If you have any of these side effects, you should tell the doctor or nurse as soon as possible that you are on or have been on an immunotherapy.
Some common side effects of nivolumab include:
- tiredness (fatigue)
- feeling sick
- loss of appetite
- weakness or lack of energy
Other ‘immune’ symptoms can range from mild to severe and include:
- itchy skin or skin rash
- diarrhoea
- stomach pain and cramping
- blood in your poo
- tiredness
- weight gain or weight loss
- heart palpitations
- yellowing of the eyes (jaundice)
- shortness of breath
The trial team will go through all the possible side effects of treatment. They’ll monitor you for any of the above symptoms and treat them straight away.
Recruitment start:
Recruitment end:
How to join a clinical trial
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Chief Investigator
Dr Graham Collins
Supported by
Cancer Research UK & UCL Cancer Trials Centre
Bristol-Myers Squibb
University College London
If you have questions about the trial please contact our cancer information nurses
Freephone 0808 800 4040